

The relative ability to support DNA synthesis was generally E-5-propenyl-dUTP [79551-91-0] .simeq. dTTP > E-5-(2-bromovinyl-dUTP) [77222-61-8] > 5-propyl-dUTP [64374-76-1] .mchgt. 2'-**fluoro-arabinonucleoside** triphosphates .mchgt. E-5-(2-bromovinyl)-araUTP [79551-90-9]. Incubation of analog triphosphates and polymerase with activated DNA suggests that, with E-5-(2-bromovinyl)-araUTP as the exception, the analogs have little effect on the subsequent ability of product DNA to serve as primer template. E-5-Propenyl-dUTP exhibited behavior the most similar to dTTP throughout these studies. Some general structure-activity relationships are discussed.

=> d his

(FILE 'HOME' ENTERED AT 10:35:23 ON 17 NOV 2000)

FILE 'HCAPLUS' ENTERED AT 10:44:09 ON 17 NOV 2000

L1 2 S FLUORO(2W)ARABINONUCLEOSIDE
L2 96 S ARABINONUCLEOSIDE
L3 2 S DEOXY(2W)L2

=> d 1-2 11

L1 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2000 ACS
AN 1990:36382 HCAPLUS
DN 112:36382
TI Preparation of 2',3'-dideoxy-2'-fluoro nucleosides as antivirals and pharmaceutical compositions containing them
IN Sterzycki, Roman Z.; Mansuri, Muzammil M.; Martin, John C.
PA Bristol-Myers Co., USA
SQ Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 316017	A2	19890517	EP 1988-118870	19881111
	EP 316017	A3	19900530		
	EP 316017	B1	19940119		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	US 4908440	A	19900313	US 1987-120051	19871112
	ZA 8808313	A	19890726	ZA 1988-8313	19881107
	FI 8805153	A	19890513	FI 1988-5153	19881109
	FI 90244	B	19930930		
	FI 90244	C	19940110		
	NO 8804995	A	19890516	NO 1988-4995	19881109
	NO 169492	B	19920323		
	NO 169492	C	19930112		
	IL 88330	A1	19950315	IL 1988-88330	19881109
	DK 8806316	A	19890513	DK 1988-6316	19881111
	AU 8825042	A1	19890525	AU 1988-25042	19881111
	AU 615960	B2	19911017		
	HU 48266	A2	19890529	HU 1988-5779	19881111
	HU 199499	B	19900228		
	JP 01153698	A2	19890615	JP 1988-284077	19881111
	DD 275874	A5	19900207	DD 1988-321728	19881111
	CZ 278366	B6	19931215	CZ 1988-7431	19881111
	CZ 278394	B6	19931215	CZ 1990-5451	19881111
	CZ 278395	B6	19931215	CZ 1990-5452	19881111
	AT 100461	E	19940215	AT 1988-118870	19881111
	ES 2061609	T3	19941216	ES 1988-118870	19881111
	SK 277919	B6	19950809	SK 1988-7431	19881111

	SK 278017	B6	19951011	SK 1990-5452	19881111
	JP 09183731	A2	19970715	JP 1997-9099	19881111
	US 4973677	A	19901127	US 1989-378331	19890711
	US 5126506	A	19920630	US 1990-581941	19900913
	US 5218106	A	19930608	US 1992-857850	19920326
	JP 06049091	A2	19940222	JP 1993-155977	19930524
	JP 2699049	B2	19980119		
	JP 06048947	A2	19940222	JP 1993-155978	19930524
	JP 2699050	B2	19980119		
PRAI	US 1987-120051		19871112		
	EP 1988-118870		19881111		
	JP 1993-155978		19881111		
	US 1989-378331		19890711		
	US 1990-581941		19900913		
OS	MARPAT 112:36382				
L1	ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2000 ACS				
AN	1981:614866 HCAPLUS				
DN	95:214866				
TI	Nucleoside analogs with clinical potential in antiviral chemotherapy.				
The	effect of several thymidine and 2'-deoxycytidine analog 5'-triphosphates on purified human (.alpha., .beta.) and herpes simplex virus (types 1, 2) DNA polymerases				
AU	Ruth, Jerry L.; Cheng, Yung Chi				
CS	Cancer Res. Cent., Univ. North Carolina, Chapel Hill, NC, 27514, USA				
SO	Mol. Pharmacol. (1981), 20(2), 415-22				
	CODEN: MOPMA3; ISSN: 0026-895X				
DT	Journal				